What are the Historical Developments and Current Growth Metrics of the Breath Biopsy Testing Market?
The breath biopsy testing market has seen considerable growth due to a variety of factors.
• The market size for breath biopsy testing has seen a significant increase lately. It is projected that it will escalate from a value of $3.18 billion in 2024 to $3.43 billion in 2025, marking a compound annual growth rate (CAGR) of 7.8%.
Factors such as governmental support, a move towards non-invasive diagnostic procedures, heightened awareness among public regarding preventive healthcare, expanding use in the field of cancer research, and growing application in metabolic disorder cases, contributed to its growth during the historic period.
What Does Future Hold for The Breath Biopsy Testing Market By 2029?
The breath biopsy testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for breath biopsy testing is set to witness a solid upswing in the coming years, expanding to $4.57 billion by 2029, with a compound annual growth rate (CAGR) of 7.5%.
Factors contributing to this growth during the projection period include an increase in both respiratory diseases and awareness of the benefits of early detection, clinical research and trial expansion, a rising aging population, and prevalence of infectious diseases. Key trends to look out for during this period encompass innovations in breath examination technology, a surge in demand for customized medicine, investments in medical infrastructure, partnerships between diagnostic corporations and hospitals, and the adoption of AI and data analytics techniques.
What Are The Primary Growth Drivers In The Breath Biopsy Testing Market?
An increase in respiratory illnesses is anticipated to fuel the expansion of the breath biopsy testing market in the future. Respiratory afflictions, which impact the lungs and airways, obstructing efficient breathing, are becoming more prevalent due to heightened environmental pollution, escalating smoking rates, and the mounting occurrence of chronic conditions such as asthma and chronic obstructive pulmonary disease (COPD). Breath biopsy tests are vital for these respiratory diseases, providing a quick, non-invasive, and potentially more precise method for identifying biomarkers linked to these diseases, thus enhancing early detection and treatment. As an example, the Centers for Disease Control and Prevention, a US-based government agency, revealed in their November 2023 report that the United States saw around 8,331 tuberculosis cases in 2022, a 5.9% rise from 2021. The incidence rate increased to 2.5 cases per 100,000 individuals, which is a 5.5% rise compared to the previous year. Hence, the escalating prevalence of respiratory diseases will act as a catalyst for the growth of the breath biopsy testing market.
What Is The Segmentation Of The Global Breath Biopsy Testing Market?
The breath biopsy testingmarket covered in this report is segmented –
1) By Type: Volatile Organic Compound Analyzers, Breath Biopsy Kits, Breath Sampler, Other Types
2) By Technology: Fuel Cell Technology, Semiconductor Sensor, Infrared (IR) Spectroscopy, Other Technologies
3) By Application: Hospitals, Clinics, Diagnostics Laboratories, Other Applications
Subsegments:
1) By Volatile Organic Compound (VOC) Analyzers: Gas Chromatography-Mass Spectrometry (GC-MS) Analyzers, Photoionization Detectors (PID), Electronic Nose Devices
2) By Breath Biopsy Kits: Sample Collection Kits, Analysis Kits For Specific Biomarkers, Packaging And Transport Kits
3) By Breath Sampler: Breath Collection Bags, Breath Sampling Tubes, Portable Breath Sampling Devices
4) By Other Types: Breath Testing Devices For Specific Conditions, Software For Data Analysis, Calibration Devices For Breath Analyzers
Pre-Book The Breath Biopsy Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Breath Biopsy Testing Market?
Key players in the breath biopsy testing market, such as breath analyzers manufacturers, are prioritizing the creation of novel products specifically aimed at uncovering asthma conditions. Breath analyzers, which serve as diagnostic tools, recognize and quantify certain compounds in a person’s breath to diagnose health issues or evaluate a person's health condition. For example, GenWorks, a healthcare solutions company based in India, introduced the FenomPro breath analyzer to the market in May 2023. This breath analyzer has an exceptional capability for quick FeNO testing, reporting results within 28 seconds. It is built for effortless usage in clinical scenarios, providing precise evaluations for the diagnosis, detection, and supervision of asthma. The FenomPro includes a rechargeable battery for easy mobility, incorporates a user-friendly display, and effectively identifies if a patient requires either treatment or a prescription for an inhaler.
Who Are the Key Players In The Breath Biopsy Testing Market?
Major companies operating in the breath biopsy testing market are:
• Drägerwerk AG & Co. KGaA
• Intoximeters Inc.
• Owlstone Medical Ltd.
• SKC Inc.
• Lifeloc Technologies Inc.
• Alcolizer Pty Ltd.
• Breathomix
• Aerocrine AB
• Bedfont Scientific Ltd.
• AK GlobalTech Corp.
• Alveo Technologies Inc.
• Andatech Pty Ltd.
• BACtrack
• Biosensia Ltd.
• Ionicon
• Ketonix AB
• Lion Laboratories Limited
• Menssana Research Inc.
• Microplex Inc.
• Quest Products Inc.
• Rapid Biosensor Systems Ltd.
• RoboScientific Ltd.
• Spirosure
What Are The Regional Insights Into The Breath Biopsy Testing Market?
North America was the largest region in the breath biopsy testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breath biopsy testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
